Alternative cancer treatment could replace chemo and surgery, study suggests
New cancer research pioneered by Memorial Sloan Kettering points to a strong alternative to chemotherapy, surgery and radiation for some forms of cancer.
Nearly 80% of patients who suffered from a variety of cancer types were successfully treated with only immunotherapy, according to a new study published in The New England Journal of Medicine.
The immunotherapy protocol successfully treated 100% of rectal cancer patients involved in the trial.
"My husband, Tommy, and I were preparing for the worst," recalled Maureen Sideris, who was diagnosed with gastroesophageal junction cancer in 2022 and subsequently became a participant in the trial.
"After being treated with only immunotherapy, I had no evidence of cancer and didn't have to undergo surgery, chemo or radiation," she said in an MSK press release. "I felt like I won the lottery!"
Dr. Andrea Cercek, a gastrointestinal oncologist, oversaw the research along with fellow gastrointestinal oncologist Dr. Luiz Diaz.
The pair sought to develop this approach in part due to the negative impacts of traditional treatment, according to the release.
"Using the standard-of-care treatment of surgery, radiation and chemotherapy to treat rectal cancer is effective," Cercek said.
"But the treatments can leave people infertile and severely affect bowel, urinary and sexual functions, as well as other aspects of daily life."
"After being treated with only immunotherapy, I had no evidence of cancer and didn't have to undergo surgery, chemo or radiation."
Participants in the trial were all patients with tumors ranging from stage 1 to stage 3, meaning the tumors had not yet spread, the release indicated.
The tumors also had a genetic mutation called mismatch repair-deficient (MMRd), which makes them particularly vulnerable to a type of immunotherapy called "checkpoint inhibitors."
This therapy "unmasks" tumor cells, MSK stated, making it easier for the patient's own immune system to recognize and kill cancer cells.
The first clinical trial testing the therapy started with only 18 patients, all of whom had rectal cancer.
"We knew there was a broad range of cancer types that had this same MMRd genetic mutation," Cercek said. "We hoped this approach could help people facing these other cancers, too."
In the expanded trial, which contained 103 patients, there were 49 rectal cancer patients and 54 patients with other types of cancer. Participants received checkpoint inhibitor infusions intravenously over the course of six months, per the release.
In all 49 rectal cancer patients, there was no evidence of cancer after immunotherapy.
Of the 54 patients with other cancers, 35 saw all signs of cancer disappear after therapy, according to a variety of tests performed for the study.
"This is a very significant response, and the results were even better than we had hoped," said Cercek. "We found that some cancer types responded extremely well to the immunotherapy, including colon and stomach cancer."
In the 20% of non-rectal cancer patients who still needed surgery post-therapy, researchers saw that the immunotherapy often shrunk the tumor and even lowered the stage classifications of some of the tumors, according to Cercek.
Timothy Yap, Ph.D., a medical oncologist at the University of Texas MD Anderson Cancer Center, agrees that the immunotherapy treatment's effectiveness for multiple kinds of cancer is "exciting."
"We are always seeking to improve treatment strategies for cancer patients through innovative clinical trials, and this is no exception," Yap, who was not involved in the study, told Fox Digital.
"Responding patients may avoid the need for surgery, chemotherapy and radiation therapy, and benefit by improving their quality of life," he said.
"This is a very significant response, and the results were even better than we had hoped."
Based on the results of the original trial with rectal patients, the immunotherapy-only approach has been incorporated into the treatment guidelines of the National Comprehensive Cancer Network, which is the doctor's group that sets cancer treatments in the U.S., the release stated.
For more Health articles, visit www.foxnews.com/health
Some of the original participants of the 2022 trial are still cancer-free today, multiple years after the initial treatment.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Advertiser readers congratulate six-year-old who beat cancer
Swindon Adver readers congratulated a six-year-old boy who has officially beaten cancer. Tommy was diagnosed with Acute Lymphoblastic Leukaemia in March 2023 and can now live without fighting each day. On April 24, Tommy rang the bell at Great Western Hospital and said the magic words: "This bell is here for you to ring, while those around you cheer and sing, already you have come so far, you're stronger than you think you are, the journeys hard make no mistake, each day small steps you need to take, with love and strength to you we say, this bell will help you on your way." We shared this truly special moment and congratulated Tommy on this happy occasion. Here's what you had to say. Helen Gibson said: 'That's excellent news. Onwards and upwards now boy, you've got this.' Sarah Plimmer said: 'Congratulations, well done to you.' Antony Thomas said: 'Well done Tommy, you're an amazing boy, bless you.' Aiden Henshaw said: 'Hard as nails, well done Tommy you warrior!' Alan Lambert said: 'Well done lad.' Michelle-Jane Banaschewsky said: 'Well done little fella, what a warrior you are.' Wendy Bain said: 'Amazing, well done young man.' Sophie said: 'Awwww what an amazing brave little boy. So nice to see something positive for once.' Leanne Waite said: 'Amazing.' Tracey Scott said: 'Wonderful news, lots of love.' Natasha Evans said: 'Awwww what fantastic news little man.' Connor Robins said: 'Brilliant news for you little man!! Must be made of metal being as strong as you are.' Mandy Lane said: 'Well done. That's amazing news to hear. Very strong young man.' Brenda Harrington said: 'Well done.' Linda Johnstone said: 'Brilliant news.' Kelly Nash said: 'Amazing news little man.' Carmel Shea said: 'What an amazing little man.' Teresa Hart said: 'Fantastic news.' Carole Green said: 'Well done Tommy!' Anne Woodward said: 'Brilliant news, brave, amazing and inspirational.' Anita Renn said: 'Most amazing boy you are Tommy.' Auriel Meyrick said: 'That's wonderful news.' Caroline Henry said: 'Lovely.' Terry Smart said: 'Fantastic news Tommy. Well done GWH.' Carolyn Sarson said: 'Brilliant news.' Siobhan Catherine said: 'Well done, what a little soldier.' Russell Watts said: 'Good lad.' Christine Smith said: 'Very well done.'
CBS News
2 days ago
- CBS News
A woman's heart suddenly stopped. Two passing nurses saved her life.
Merryl Hoffman knew she was taking good care of her heart. The 63-year-old attorney didn't smoke or drink, and she was an avid hiker who used to run marathons and other distance races. In her 40s, she had been diagnosed with a leaky mitral valve and underwent surgery to repair it. Every year since, she has seen a cardiologist to check her heart and its function. The reports always came back clear. When Hoffman left her apartment on Manhattan's Upper East Side on Oct. 23, 2025, her heart was the last thing on her mind. She was saddled with her work bag and purse, hightailing it to the subway station so she could make it to work on time. That's when her memory of the day ends. Shortly into her walk, Hoffman experienced a sudden cardiac arrest. Her heart stopped beating. She collapsed to the ground. Doctors later told her it was a severe arrhythmia that could have been fatal — if not for where Hoffman fell. Hoffman had collapsed outside Memorial Sloan Kettering Cancer Center's Breast and Imaging Center, about two and a half blocks from her subway station. A patient care technician and a passing runner immediately rushed to her aid. Then, Memorial Sloan Kettering nurses Sabrina Castle and Gianna Formisano stumbled upon the scene while walking to work. "We were so shocked. When we were walking up, people were like 'Nurses, nurses!' We didn't know what we were walking into," Formisano said. "People were grabbing our coffee, taking our bags. It was out of a movie, the way that they were like 'Oh, thank God you're here.'" Sabrina Castle and Gianna Formisano outside the Memorial Sloan Kettering Cancer Center. Memorial Sloan Kettering "They absolutely saved my life" Formisano and Castle took over performing CPR, keeping Hoffman's heart manually beating. She didn't have a pulse, and she had hit her head when she collapsed. The nurses also instructed one of the other bystanders to call an ambulance. Early CPR increases survival for patients in cardiac arrest by "at least two or three fold," said Dr. Jessica Hennessey, a cardiologist at NewYork-Presbyterian/Columbia University Irving Medical Center. Early CPR means that blood flow to the brain and heart continues, preserving the health of those organs. Bystanders in a medical emergency should call 911 and immediately start CPR, Hennessey advised. CPR can be done with mouth-to-mouth or with just chest compressions, Hennessey said. After five minutes that "felt like forever," the ambulance arrived, Formisano said. Castle and Formisano helped the EMTs load Hoffman into the ambulance. Then, she was taken to NewYork-Presbyterian's cardiac care unit for further treatment. For the small crowd, the day carried on. Castle and Formisano headed to work. After a few hours, they called NewYork-Presbyterian to see if they could find out more about Hoffman's status. They went to the hospital and spoke to a nurse there. "She was like, 'You got her back. She's intubated, she's alive, you saved her life,'" Castle recalled. Hoffman was still unconscious. She told CBS News that she didn't wake up until five days after the collapse. Her family told her that she had been rushed into surgery. Doctors told her that her heart had stopped for several minutes -- and the actions of Castle, Formisano and other bystanders had saved her. "Without them, I was told, there was no doubt I would have died or been brain dead," Hoffman said. "They absolutely saved my life." Hoffman had an implantable cardioverter-defibrillator placed in her chest to prevent further cardiac arrests. The device shocks the heart if it detects an irregular heartbeat. She also began cardiac rehabilitation. Shortly after, she returned to work. Life began to get back to normal but one question was constantly at the back of her mind: Who had helped save her? A chance reunion While in cardiac rehabilitation, Hoffman found herself telling the story of the strangers who had helped her. A physiologist there overheard her talking about it and thought the story sounded familiar. His girlfriend was friends with two nurses who had helped a woman matching Hoffman's description. After some back and forth, the physiologist connected Hoffman with Castle and Formisano. The trio immediately made plans to get dinner. Hoffman's husband joined them for the meal. There, the nurses were able to fill in the gaps of the October morning when Hoffman collapsed. Sabrina Castle, Merryl Hoffman and Gianna Formisano at the site where Hoffman collapsed. Sabrina Castle and Gianna Formisano "It was very jarring, when they gave my husband and I the blow-by-blow of that morning. There were things we did not know," Hoffman said. "It was pretty incredible." Since that dinner, the women have stayed in touch. Recently, Castle and Formisano even passed Hoffman on the same block where she had collapsed. The three took a photo at the site. "We were like, 'Wow, this is really crazy,'" Formisano said. "'We're running into you on the same spot, on your way to work, on our way to work, but now you're alive and well and in a much different state than when we met you the first time.'"
Medscape
4 days ago
- Medscape
Durvalumab Plus FLOT Improves Early Upper-GI Cancer
Adding the immune checkpoint inhibitor durvalumab (Imfinzi) to the standard chemotherapy regimen of fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) improved event-free survival (EFS) in patients with resectable, early–stage adenocarcinoma of the upper-gastrointestinal (GI) tract. Experts say these interim results, which were presented by Yelena Janjigian, MD, at the American Society of Clinical Oncology (ASCO) 2025 annual meeting in Chicago, make the case for a new standard for treating these cancers. The phase 3 MATTERHORN study 'supports the global adoption of perioperative durvalumab plus FLOT for patients with localized gastric and gastroesophageal junction adenocarcinoma,' said Janjigian of the Memorial Sloan Kettering Cancer Center in New York City at the plenary session of the meeting. The study was published simultaneously in The New England Journal of Medicine . The goal of the study is to address the low cure rates for early-stage gastroesophageal cancer, which remain below 50% with most recurrences occurring within 2 years after surgery, said Janjigian, who is also an author of the new paper. MATTERHORN enrolled 948 people with stage II, III and IVA resectable gastric cancer and gastroesophageal junction cancer, randomizing them to two regimens: Durvalumab 1500 mg plus FLOT before surgery, followed by two cycles of durvalumab 1500 mg every 4 weeks plus FLOT, and then 10 cycles of durvalumab 1500 mg every 4 weeks; or placebo plus FLOT before surgery, and then two cycles of placebo plus FLOT followed by 10 cycles of placebo. Applying Immunotherapy in Early-Stage Disease 'We know that immunotherapy works for stage IV disease in an advanced setting,' Janjigian said at a press conference before the plenary session. 'In metastatic disease, we've been using anti-PD-1 agents for years, but they have not been proven to help patients with early-stage cancer.' In MATTERHORN, patients in the durvalumab group had a 29% relative risk reduction in 2-year EFS, which was the primary endpoint. That risk reduction was 67.4% for the treatment group vs 58.5% for the placebo group ( P <.001), Janjigian said at the plenary session. Because the results are interim, the median EFS with durvalumab was not reached, which means that more than half of the patients in the durvalumab plus FLOT group had not had a cancer recurrence at 2 years. The median EFS for the placebo group was 32.8 months. Among secondary endpoints, 2-year overall survival was 75.7% in the durvalumab group vs 70.4% in the placebo group, a 22% advantage for the former, Janjigian said, but that has not yet reached statistical significance in the interim analysis. The median overall survival rate has not yet been reached because there have not been enough deaths in that group to calculate it, Janjigian told Medscape Medical News . In the placebo group, 2-year overall survival was 47.2 months. 'Survival data will continue to be followed and will be updated,' she said. 'There was a consistent event-free survival benefit with the addition of durvalumab across all subgroups, including patients aged 65 or older, patients enrolled in Asia, and patients with anti-PDL-1 and PDL-1- negative and gastroesophageal junction tumors,' Janjigian said at the plenary session. About 19% of the study participants were in Asia, 53% in Europe, 19% in South America, and 9% in North America. 'All hazard ratio estimates for the subgroups were < 1, reinforcing the consistency and robustness of the treatment effect,' Janjigian said. Safety outcomes were similar in both the durvalumab and placebo groups, Janjigian said. 'Grade 3 and 4 treatment-related adverse events occurred in 60% of patients in the durvalumab arm and 59% in the placebo arm,' she said. Grade 3 or 4 immune-mediated adverse events occurred more frequently in patients in the durvalumab group, she added: 7% vs 4%. The addition of durvalumab did not interfere with the delivery of FLOT in the perioperative setting, and, in the adjuvant phase, 52% of patients in the durvalumab group completed 1 year of therapy, as did 51% of patients in the placebo group, she said. A New Standard? 'To put it simply, the MATTERHORN trial moves the field forward and establishes perioperative durvalumab plus FLOT as the new standard for this patient population,' Samuel Klempner, MD, director of Gastroesophageal Medical Oncology and associate professor at Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, said in comments as the discussant at the plenary session. 'While overall survival is immature, I'm very optimistic that MATTERHORN will show a statistical improvement in overall survival based on the shape of the curves, the strong statistical design, and observations from other phase 3 perioperative gastric trials like RESOLVE and PRODIGY, where longer follow-up improved the hazard ratio and enhanced the significance of the P value,' Klempner said. The RESOLVE trial confirmed the survival advantage of perioperative-S-1 and oxaliplatin (SOX) and adjuvant-SOX compared with the standard adjuvant-postoperative capecitabine-and-oxaliplatin regimen in gastric or gastroesophageal junction cancer. The PRODIGY trial found that neoadjuvant chemotherapy with docetaxel, oxaliplatin, and S-1 followed by surgery and adjuvant S-1 chemotherapy improved progression-free survival over surgery followed by adjuvant S-1 for patients with resectable locally advanced gastric cancer. The MATTERHORN population 'looks like patients in the clinic,' and the similarity in patient dispositions between the study groups was important, said Klempner. 'To me, this says that academic and community oncologists and our surgical colleagues can feel confident that adding durvalumab to FLOT does not impact our ability to complete neoadjuvant FLOT, get to surgery, achieve our zero resection, or complete adjuvant therapy,' he said. 'I also want to stake the claim for D-FLOT as the name for this new standard regimen,' he added to loud applause in the session. 'This is a pivotal trial in upper GI cancer patients in a space that's really been taking center stage in recent years with many recent advances,' Pamela Kunz MD, PhD, director of the Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center in New Haven, Connecticut, said at a press conference before the presentation. 'This is going to change the standard of care for this patient population.' She added that physicians must carefully select patients for durvalumab plus FLOT treatment. 'Can all patients tolerate a four-drug treatment?' Kunz asked. 'The study demonstrated it was reasonably well tolerated, but in terms of the patients in front of us, we need to think about them.' This study was funded by AstraZeneca. Janjigian reported disclosed financial relationships with AbbVie, AmerisourceBergen, Arcus Biosciences, Ask-Gene Pharma, Astellas Pharma, AstraZeneca, Basilea Pharmaceutica, Bayer, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Clinical Care Options, Daiichi Sankyo, eChinaHealth, ED MedResources, EISAI, Eli Lilly and Co., Genentech, Geneos Therapeutics, GlaxoSmithKline, Guardant Health, H.C. Wainwright & Co., Imedex, Imugene, Inspirna, Lynx Health, Merck, Merck Serono, Mersana Therapeutics, Pfizer, Sanofi Genzyme, Seagen, Silverback Therapeutics, Transcenta, and Zymeworks. Klempner reported relationships with Nuvalent, Merck Serano, Amgen, Astellas Pharma, AstraZeneca, BeiGene, Bristol Myers Squibb, Daiichi Sankyo UCB Japan, Eisai, Elevation Oncology, Gilead Sciences, I-Mab, Merck, Novartis, SERVIER, Taiho Oncology, Arcus Biosciences, Leap Therapeutics, and Mersana. Disclosures for Kunz were not available at press time.
